Adipocytokines, gut hormones and growth factors in anorexia nervosa

Clinica Chimica Acta

Volumn 412, Issue 19-20, 2011, Pages 1702-1711

  Kowalska, Irina ^a   Karczewska Kupczewska, Monika ^a   Straczkowski, Marek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adipocytokines; Anorexia nervosa; Gut hormones; Insulin sensitivity; Regulation of appetite

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 21; GASTROINTESTINAL HORMONE; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GROWTH DIFFERENTIATION FACTOR 15; GROWTH FACTOR; LEPTIN; NEUROTROPHIN; OBESTATIN; SOMATOMEDIN C;

ANOREXIA NERVOSA; APPETITE; DIET THERAPY; DISEASE COURSE; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; HORMONE ACTION; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALNUTRITION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ADIPOKINES; ANOREXIA NERVOSA; GHRELIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 79960634755     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.007     Document Type: Review

References (172)

1. Yager J., Anderson A.E. Anorexia nervosa. N Engl J Med 2005, 353:1481-1488.
2. Diagnostic and statistical manual of mental disorders 2000, DSM-IV-TR., American Psychiatric Association, Washington, D.C. 4th ed.
3. Halami K.A., Eckert E., Marchi P., Sampugnaro V., Apple R., Cohen J. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch Gen Psychiatry 1991, 48:712-718.
4. Kerem N.C., Katzman D.K. Brain structure and function in adolescents with anorexia nervosa. Adolesc Med 2003, 14:109-118.
5. Ohrman P., Kersting A., Suslow T., et al. Proton magnetic resonance spectroscopy in anorexia nervosa: correlation with cognition. Neuroreport 2004, 15:549-553.
6. Chui H.T., Christensen B.K., Zipursky R.B., et al. Cognitive function and brain structure in females with a history of adolescent-onset of anorexia nervosa. Pediatrics 2008, 122:e426-e437.
7. Castillo M., Scheen A., Lefebvre P.J., Luyckx A.S. Insulin-stimulated glucose disposal is not increased in anorexia nervosa. J Clin Endocrinol Metab 1985, 60:311-331.
8. Karczewska-Kupczewska M., Straczkowski M., Adamska A., et al. Insulin sensitivity, metabolic flexibility, and serum adiponectin concentration in women with anorexia nervosa. Metabolism 2010, 59:473-477.
9. Delporte M.L., Brichard S.M., Hermans M.P., Beguin C., Lambert M. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol 2003, 58:22-29.
10. Fukushima M., Nakai Y., Taniguchi A., Imura H., Nagata I., Tokuyama K. Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis. Metabolism 1993, 42:1164-1168.
11. Housova J., Anderlova K., Krizova J., et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2005, 90:1366-1370.
12. Tagami T., Satoh N., Usui T., Yamada K., Shimatsu A., Kuzuya H. Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2004, 89:1833-1837.
13. Misra M., Miller K.K., Almazan C., et al. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 2004, 89:3486-3495.
14. Dostalova I., Smitka K., Papezova H., Kvasnickova H., Nedvidkova J. Increased insulin sensitivity in patients with anorexia nervosa: the role of adipocytokines. Physiol Res 2007, 56:587-594.
15. Franssila-Kallunki A., Rissanen A., Ekstrand A., et al. Fuel metabolism in anorexia nervosa and simple obesity. Metabolism 1991, 40:689-694.
16. Pannacciulli N., Vettor R., Milan G., et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 2003, 88:1748-1752.
17. Zhang Y., Proneca R., Maffei M., Barone M., Leopold L., Fridmann J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
18. Farooqi I.S., Jeeb S.A., Langmack G., et al. Effect of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341:879-884.
19. Bluher S., Mantzaros C.S. Leptin in humans: lessons from translational research. Am J Clin Nutr 2009, 89(Suppl):991S-997S.
20. Muoio D.M., Dohm G.L. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002, 16:653-666.
21. Farooqi I.S., O'Rahilly S. Leptin: a pivotal regulator of energy hemostasis. Am J Clin Nutr 2009, 89(suppl):480S-484S.
22. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570-578.
23. Chehab F.F., Lim M.E., Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996, 12:318-320.
24. Strobel I., Isaad T., Camoin L., Ozata M., Shosberg A.D. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998, 18:213-215.
25. Welt C.K., Chan J.L., Bullen J., et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004, 351:987-997.
26. Chan J.L., Mantzaros C.S. Role of leptin in energy-deprivation states: normal human physiology and clinical implication for hypothalamic amenorrhea and anorexia nervosa. Lancet 2005, 366:74-85.
27. Chan J.L., Heist K., DePaoli A.M., Veldhuis J.D., Mantzaros C.S. The role of falling leptin levels in neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003, 111:1409-1421.
28. Yannakoulia M., Yiannakouris N., Bluher S., et al. Body fat mass and macronutritient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88:1730-1736.
29. Kratzsch J., Lammert A., Bottner A., et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty and adolescence. J Clin Endocrinol Metab 2002, 87:4587-4594.
30. Dostalova I., Kavalkova P., Haluzikova D., et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008, 93:3627-3632.
31. Krizova J., Papezova H., Haluzikova D., et al. Soluble leptin receptor in patient with anorexia nervosa. Endocrine Res 2002, 28:199-205.
32. Modan-Moses D., Stain D., Pariente C., et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab 2007, 92:1843-1847.
33. Haas V., Onur S., Paul T., et al. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am J Clin Nutr 2005, 81:889-896.
34. Holtkamp K., Hebebrand J., Mika C., Heer M., Heussen N., Herpertz-Dahlmann B. High serum leptin level subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa. Psychoneuroendocrinology 2004, 29:791-797.
35. Mantzoros C., Filer J.S., Lesem M.D., Brewerton T.D., Jimerson D.C. Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance in weight gain. J Clin Endocrinol Metab 1997, 82:1845-1851.
36. Van Elburg A.A., Kas M.J.H., Hillebrand J.J.G., Eijkemans R.J.C., van Engeland H. The impact of hyperactivity and leptin on recovery from anorexia nervosa. J Neural Trans 2007, 114:1233-1237.
37. Casper R. The "drive for activity" and "restlessness" in anorexia nervosa. J Affect Disord 2006, 92:99-107.
38. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
39. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
40. Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120:803-812.
41. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
42. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
43. Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
44. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
45. Tsao T.S., Tomas E., Murrey H.E., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003, 278:50810-50817.
46. Hara K., Horikoshi M., Yamauchi T., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
47. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
48. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52:1779-1785.
49. Haque W.A., Shimomura I., Matsuzawa Y., Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395-2398.
50. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
51. Kumada M., Kihara S., Sumitsuji S., et al. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
52. Adamczak M., Wiecek A., Funahashi T., Chudek J., Kokot F., Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16:72-75.
53. Kowalska I., Straczkowski M., Nikolajuk A., Krukowska A., Kinalska I., Gorska M. Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean non-diabetic offspring of type 2 diabetic subjects. Eur J Endocrinol 2006, 154:319-324.
54. Salmenniemi U., Zacharova J., Ruotsalainen E., et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2005, 90:4216-4223.
55. Højlund K., Frystyk J., Levin K., Flyvbjerg A., Wojtaszewski J.F., Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006, 49:1283-1291.
56. Bosy-Westphal A., Brabant G., Haas V., et al. Determinants of plasma adiponectin levels in patients with anorexia nervosa examined before and after weight gain. Eur J Nutr 2005, 44:355-359.
57. Saito K., Arata S., Hosono T., et al. Adiponectin plays an important role in efficient energy usage under energy shortage. Biochim Biophys Acta 2006, 1761:709-716.
58. Iwahashi H., Funahashi T., Kurokawa N., et al. Plasma adiponectin levels in women with anorexia nervosa. Horm Metab Res 2003, 35:537-540.
59. Dolezalova R., Lacinova Z., Dolinkova M., et al. Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression. Clin Endocrinol 2007, 67:674-678.
60. Bootcov M.R., Bauskin A.R., Valenzuela S.M., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1977, 94:11514-11519.
61. Ding Q., Mracek T., Gonzalez-Muniesa P., et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009, 150:1688-1696.
62. Böttner M., Suter-Crazzolara C., Schober A., Unsicker K. Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 1999, 297:103-110.
63. Kim K.S., Baek S.J., Flake G.P., Loftin C.D., Calvo B.F., Eling T.E. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 2002, 122:1388-1398.
64. Zimmers T.A., Jin X., Hsiao E.C., McGrath S.A., Esquela A.F., Koniaris L.G. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005, 23:543-548.
65. Mimeault M., Batra S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010, 224:626-635.
66. Brown D.A., Moore J., Johnen H., et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 2007, 56:753-764.
67. Bauskin A.R., Brown D.A., Kuffner T., et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006, 66:4983-4986.
68. Johnen H., Lin S., Kuffner T., et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007, 13:1333-1340.
69. Dostálová I., Kaválková P., Papezová H., Domluvilová D., Zikán V., Haluzík M. Association of macrophage inhibitory cytokine-1 with nutritional status, body composition and bone mineral density in patients with anorexia nervosa: the influence of partial realimentation. Nutr Metab 2010, 7:34.
70. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
71. Davenport A.P., Bonner T.I., Foord S.M., et al. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev 2005, 57:541-546.
72. Kojima M., Kangawa K. Ghrelin: structure and function. Physiol Rev 2005, 85:495-522.
73. Tritos N.A., Kokkotou E.G. The physiology and potential clinical applications of ghrelin, a novel peptide hormone. Mayo Clin Proc 2006, 81:653-660.
74. Patterson M., Murphy K.G., le Roux C.W., Ghatei M.A., Bloom S.R. Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab 2005, 90:2205-2211.
75. Korbonits M., Goldstone A.P., Gueorguiev M., Grossman A.B. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004, 25:27-68.
76. Baldanzi G., Filigheddu N., Cutrupi S., et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002, 159:1029-1037.
77. Mackelvie K.J., Meneilly G.S., Elahi D., Wong A.C., Barr S.I., Chanoine J.P. Regulation of appetite in lean and obese adolescents after exercise: role of acylated and desacyl ghrelin. J Clin Endocrinol Metab 2007, 92:648-654.
78. Giovambattista A., Gaillard R.C., Spinedi E. Ghrelin gene-related peptides modulate rat white adiposity. Vitam Horm 2008, 77:171-205.
79. St-Pierre D.H., Bastard J.P., Coderre L., et al. Association of acylated ghrelin profiles with chronic inflammatory markers in overweight and obese postmenopausal women: a MONET study. Eur J Endocrinol 2007, 157:419-426.
80. Asakawa A., Inui A., Fujimiya M., et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005, 54:18-24.
81. Chen C.Y., Chao Y., Chang F.Y., Chien E.J., Lee S.D., Doong M.L. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med 2005, 16:695-699.
82. Toshinai K., Yamaguchi H., Sun Y. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 2006, 147:2306-2314.
83. Zhang J.V., Ren P.G., Avsian-Kretchmer O., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310:996-999.
84. Bresciani E., Rapetti D., Donà F., et al. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest 2006, 29:RC16-RC18.
85. Chartrel N., Alvear-Perez R., Leprince J., et al. Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". Science 2007, 315:766.
86. Seoane L.M., Al-Massadi O., Pazos Y., Fagotto U., Casanueva F.F. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006, 29:RC13-RC15.
87. Gourcerol G., St-Pierre D.H., Tache Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)?. Regulat Pept 2007, 141:1-7.
88. Garg A. The ongoing saga of obestatin: is it a hormone?. J Clin Endocrinol Metab 2007, 92:3396-3398.
89. Cummings D.E. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006, 89:71-84.
90. Shiiya T., Nakazato M., Mizuta M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87:240-244.
91. Cummings D.E., Weigle D.S., Frayo R.S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346:1623-1630.
92. Nakahara T., Harada T., Yasuhara D. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 2008, 64:252-255.
93. Otto B., Cuntz U., Fruehauf E., et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001, 145:669-673.
94. Tolle V., Kadem M., Bluet-Pajot M.T., et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 2003, 88:109-116.
95. Misra M., Miller K.K., Kuo K., et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005, 289:E347-E356.
96. Tanaka M., Nakahara T., Kojima S., et al. Effect of nutritional rehabilitation on circulating ghrelin and growth hormone levels in patients with anorexia nervosa. Regul Pept 2004, 122:163-168.
97. Janas-Kozik M., Krupka-Matuszczyk I., Malinowska-Kolodziej I., Lewin-Kowalik J. Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa. Regul Pept 2007, 140:43-46.
98. Broglio F., Gianotti L., Destefanis S., et al. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol 2004, 60:592-599.
99. Hotta M., Ohwada R., Akamizu T., Shibasaki T., Takano K., Kangawa K. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J 2009, 56:1119-1128.
100. Dostalova I., Haluzik M. The role of ghrelin in the regulation of food intake in patients with obesity and anorexia nervosa. Physiol Res 2009, 58:159-170.
101. Nakai Y., Hosoda H., Nin K., et al. Plasma levels of active form of ghrelin during oral glucose tolerance test in patients with anorexia nervosa. Eur J Endocrinol 2003, 149:R1-R3.
102. Harada T., Nakahara T., Yasuhara D., et al. Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biol Psychiatry 2008, 63:245-247.
103. Koyama K.I., Yasuhara D., Nakahara T., et al. Changes in acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to total ghrelin with short-term refeeding in female in patients with restricting-type anorexia nervosa. Horm Metab Res 2010, 42:595-598.
104. Tanaka M., Nakahara T., Yasuhara D., et al. Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology 2003, 28:829-835.
105. Otto B., Tschop M., Cuntz U. Similar fasting ghrelin levels in binge eating/purging anorexia nervosa and restrictive anorexia nervosa. Psychoneuroendocrinology 2004, 29:692-693.
106. Germain N., Galusca B., Grouselle D., et al. Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology 2009, 34:413-419.
107. Sedlackova D., Kopeckova J., Papezova H., et al. Changes of plasma obestatin, ghrelin and NPY in anorexia and bulimia nervosa patients before and after a high-carbohydrate breakfast. Physiol Res Oct 15 2010, (epub ahead of print).
108. Monteleone P., Serritella C., Martiadis V., Scognamiglio P., Maj M. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. J Clin Endocrinol Metab 2008, 93:4418-4421.
109. Williams D.L., Cummings D.E., Grill H.J., Kaplan J.M. Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 2003, 144:2765-2767.
110. Shiiya T., Nakazato M., Mizuta M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87:240-244.
111. Murdolo G., Lucidi P., Di Loreto C., et al. Insulin is required for prandial ghrelin suppression in humans. Diabetes 2003, 52:2923-2927.
112. Nakai Y., Hosoda H., Nin K., et al. Short-term secretory regulation of the active form of ghrelin and total ghrelin during an oral glucose tolerance test in patients with anorexia nervosa. Eur J Endocrinol 2004, 150:913-914.
113. Tanaka M., Tatebe Y., Nakahara T., et al. Eating pattern and the effect of oral glucose on ghrelin and insulin secretion in patients with anorexia nervosa. Clin Endocrinol 2003, 59:574-579.
114. Misra M., Miller K.K., Herzog D.B., et al. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J Clin Endocrinol Metab 2004, 89:1605-1612.
115. Nedvidkova J., Krykorkova I., Bartak V., et al. Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab 2003, 88:1678-1682.
116. Saad M.F., Bernaba B., Hwu C.M., et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002, 87:3997-4000.
117. St-Pierre D.H., Karelis A.D., Coderre L., et al. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J Clin Endocrinol Metab 2007, 92:264-269.
118. Karczewska-Kupczewska M., Straczkowski M., Adamska A., et al. Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa. Eur J Endocrinol 2010, 162:235-239.
119. Ikezaki A., Hosoda H., Ito K., et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002, 51:3408-3411.
120. Ukkola O. Ghrelin and the metabolic balance. J Endocrinol Invest 2005, 28:849-852.
121. Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
122. Gauna C., Delhanty P.J., Hofland L.J., et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005, 90:1055-1060.
123. Gauna C., Meyler F.M., Janssen J.A., et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004, 89:5035-5042.
124. Nakahara T., Harada T., Yasuhara D., et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 2008, 64:252-255.
125. Dardennes R.M., Zizzari P., Tolle V., et al. Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with Anorexia nervosa: association with subtype, body-mass index, severity and age of onset. Psychoneuroendocrinology 2007, 32:106-113.
126. Hassouna R., Zizzari P., Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol 2010, 22:793-804.
127. Ando T., Komaki G., Nishimura H., et al. A ghrelin gene variant may predict crossover rate from restricting-type anorexia nervosa to other phenotypes of eating disorders: a retrospective survival analysis. Psychiatr Genet 2010, 20:153-159.
128. Müller T.D., Tschöp M.H., Jarick I., et al. Genetic variation of the ghrelin activator gene ghrelin O-acyltransferase (GOAT) is associated with anorexia nervosa. J Psychiatr Res Oct 28 2010, (epub ahead of print).
129. Melmed S. Insulin-like growth factor-I - a prototypic peripheral-paracrine hormone. Endocrinology 1999, 140:3879-3880.
130. Boisclair Y.R., Rhodas R.P., Ueki I., Wang J., Ooi G.T. The acid labile subunit (ALS) of the 150kDA IGF-I binding protein complex: an important but forgotten component of the circulating IGF-I system. J Endocrinol 2001, 170:63-70.
131. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin like growth-factors and the skeleton. Endoc Rev 2008, 29:535-559.
132. Ohlsson C., Mohan S., Sjorgen K., et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009, 30:494-535.
133. Sjorgen K., Wallenius K., Liu J.L., et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001, 50:1539-1545.
134. Yakar S., Liu J.L., Fernandez A.M., et al. Liver specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50:1110-1118.
135. Yakar S., Setser J., Zhao H., et al. Inhibition of growth hormone action improves insulin insensitivity in liver IGF-I deficient mice. J Clin Invest 2004, 113:96-105.
136. Kaplan S.A., Cohen P. The somatomedin hypothesis 2007: 50years later. J Clin Endocrinol Metab 2007, 92:4529-4535.
137. Stoving R.K., Chen J.W., Glintborg D., et al. Bioactive insulin-like growth factor (IGF) I and IGF-I binding protein-1 in anorexia nervosa. J Clin Endocrinol Metab 2007, 92:2323-2329.
138. Misra M., Miller K.K., Bjornson J., et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effect on bone metabolism. J Clin Endocrinol Metab 2003, 88:5615-5623.
139. Fazeli P.K., Misra M., Goldstein M., et al. Fibroblast Growth Factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 2010, 95:369-374.
140. Scacchi M., Pincelli A., Caumo A., et al. Spontaneous growth hormone secretion in anorexia nervosa. J Clin Endocrinol Metab 1997, 82:3225-3229.
141. Stoving R.K., Veldhuis J.D., Flyvbjerg A., et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process of irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin like growth factor I axis. J Clin Endocrinol Metab 1999, 84:2056-2063.
142. Stoving R.K., Andersen M., Flyvbjerg A., et al. Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa. Clin Endo (Oxf) 2002, 56:391-396.
143. Fazeli P.K., Lawson E.A., Prabhakaran N., et al. Effect of recombinant human growth hormone in anorexia nervosa: a randomized-placebo controlled study. J Clin Endocrinol Metab 2010, 95:4889-4897.
144. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionally history and roles in development, metabolism and disease. Cell Tissue Res 2010, 342:1-11.
145. Kliewer S.A., Mangelsdorf D.J. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010, 91(suppl):254S-257S.
146. Kharitonenkov A., Shiyanova T.C., Koesber A., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 11:1627-1635.
147. Coskun T., Bina H.A., Schnaider M.A., et al. Fibroblast growth factor 21 corrects obesity in mica. Endocrinology 2008, 149:6018-6027.
148. Galman C., Ludasen T., Kharitonenkov A., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in me. Cell Metab 2008, 8:169-174.
149. Zhang X., Yeung D.C., Karpisek M., et al. Serum FGF21 levels are increased in obesity and are independently associated with metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
150. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., DeFronzo R.A., Tripathy D. Circulating fibroblast growth factor 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
151. Fisher F.M., Chiu P.C., Antonellis P.J., et al. Obesity is a fibroblast growth factor 21(FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
152. Mai K., Schwartz F., Bobbert T., et al. Relation between fibroblast growth factor-21, adiposity, metabolism and weight reduction. Metabolism 2011, 60:306-311.
153. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic state. Cell Metab 2007, 5:426-437.
154. Inagaki T., Dutchak P., Zhao G., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
155. Inagaki T., Liu V.Y., Goetz R., Mohammadi M., Mangelsdorf D.J., Kliewer S.A. Inhibition of growth hormone signaling by the fasting induced hormone FGF21. Cell Metab 2008, 8:77-83.
156. Nocker W.A., Renz H. Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigations. Clin Chim Acta 2005, 352:49-74.
157. Lyons W.E., Mamounas L.A., Ricaurte G.A., et al. Brain-derived neurotrophic factor deficient-mice develop aggressiveness and hyperphagia in conjuction with brain serotonergic abnormalities. Proc Natl Acad Sci 1999, 96:15239-15244.
158. Nakagawa T., Tsuchida A., Itakura Y., et al. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes 2000, 49:436-444.
159. Nonomura T., Tsuchida A., Ono-Kishino M., Nakagawa T., Taiji M., Noguhi H. Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int J Exp Diab Res 2001, 2:201-209.
160. Kernie S.G., Liebl D.J., Parada L.F. BDNF regulates heating behavior and loco motor activity in mice. EMBO J 2000, 19:1290-1300.
161. Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragonow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 1997, 49:71-81.
162. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., et al. Brain-derived neurotrophic factor and type 2 diabetes. Diabetologia 2007, 50:431-438.
163. Biessels G.J., Steakenborg S., Brunner E., Brayne C., Scheltens C. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
164. Matthews V.B., Astrom M.B., Chan M.H.S., et al. Brain-derived neurotrophic factor is produced by skeletal muscles in response to contraction and enhances fat oxidation via activation of AMPK. Diabetologia 2009, 52:1409-1418.
165. Pedersen B.K., Pedersen M., Krabbe K.S., Bruunsgaard H., Mathwes H.B., Febbraio M.A. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009, 94:1153-1169.
166. Ehrlich S., Salbach-Andrae H., Eckart S., et al. Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. J Psychiatr Neurosci 2009, 34:323-329.
167. Nakazato M., Hashimoto K., Yoshimura K., et al. No change between serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. Prog Neuropsycholpharmacol Biol Psychiatry 2006, 30:1117-1121.
168. Nakazato M., Tchanturis K., Schmidt U., et al. Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. Psychol Med 2009, 36:1029-1035.
169. Monteleone P., Fabrazzo M., Martiadis V., et al. Circulating brain-derived neurotrophic factor is decreased in women with anorexia nervosa and bulimia nervosa but not in women with binge-eating disorder: relationship to co-morbid depression, psychopathology and hormonal variables. Psychol Med 2005, 35:897-905.
170. Mercader J.M., Fernandez-Aranda F., Gratacos M., et al. Correlation of BDNF blood levels with interceptive awareness and maturity fears in anorexia and bulimia nervosa patients. J Neural Transm 2010, 117:505-512.
171. Ribases M., Gratacos M., Fernandez-Aranada F., et al. Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European population. Eur J Hum Genet 2005, 13:428-434.
172. Mercader J.M., Ribases M., Gratacos M., et al. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia nervosa and bulima nervosa. Gen Brain Behav 2007, 6:706-716.